



Eleison Pharmaceuticals Announces the Appointment of Ross Donehower, MD, Eugenie Kleinerman, MD, and Kurt Weiss, MD, to its Science Advisory Board

Princeton, NJ, September 9, 2011 -- Eleison Pharmaceuticals, Inc., a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced the appointments of Dr. Ross Donehower, Dr. Eugenie Kleinerman, and Dr. Kurt Weiss to the company's Science Advisory Board.

"We are pleased to announce several new appointments to our Scientific Advisory Board. These are experienced academic clinical research experts who can help us on our two existing drug development programs (glufosfamide for pancreatic cancer, and Inhaled Lipid-complexed Cisplatin for pediatric osteosarcoma) and can help us evaluate new opportunities for late stage orphan oncology drugs," said Forrest Anthony, MD, PhD, Chief Medical Officer and President of Eleison Pharmaceuticals.

Dr. Ross Donehower is Director of the Division of Medical Oncology at The Johns Hopkins Oncology Center, Director of the Medical Oncology Fellowship Training Program, and Professor of Oncology at The Johns Hopkins University School of Medicine. The author of over 100 publications, Dr. Donehower's research focus concerns the pharmacology of chemotherapeutic drugs, especially for gastrointestinal cancers. He pioneered the first clinical studies of paclitaxel and many other novel anticancer agents.

Dr. Eugenie Kleinerman is the Mosbacher Professor and Head of the Division of Pediatrics at M. D. Anderson. She was recruited to M. D. Anderson in 1984 from the NCI-Frederick Cancer Research facility. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particularly osteosarcoma. She pioneered the use of liposome-encapsulated MTP-PE for children with osteosarcoma lung metastases. The success of these trials led to the recent approval of liposomal MTP-PE by the European Medicine Agency, the first improvement in long term survival of children with this disease in over 20 years. She is a pioneer in the research of aerosol drug delivery for chemotherapy and gene therapy of childhood cancers.

Dr. Kurt R. Weiss, is Assistant Professor of Orthopaedic Surgery at the University of Pittsburgh Medical Center, and Director of the Cancer Stem Cell Laboratory at the Stem Cell Research Center. He is in a full-time practice in musculoskeletal oncology with 60% clinical effort and 40% basic science/clinical research effort. He previously has worked in the laboratory of Lee Helman, MD at the Pediatric Oncology branch of the National Cancer Institute, and at University of Texas MD Anderson Cancer with Eugenie Kleinerman to evaluate various therapeutics for osteosarcoma and other cancers. He is also active in fund-raising efforts for cancer research, and as an inspirational speaker.

About Eleison Pharmaceuticals:

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" indications, providing new hope for patients with rare life-threatening diseases. Founded in 2008 and headquartered in Princeton, NJ, Eleison is in discussions to acquire other promising programs for rare cancers.

Forward Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

SOURCE: Eleison Pharmaceuticals, Inc.

CONTACT: Eleison Pharmaceuticals, Inc.
Corporate Communications
103 Carnegie Center, Suite 300
Princeton, NJ 08504
215-416-7620
info@eleison-pharma.com